Abstract
Central nervous system (CNS) metastasis from systemic cancers can involve the brain parenchyma, leptomeninges, or the dura. Neoplastic meningitis (NM), also known by different terms, including leptomeningeal carcinomatosis and carcinomatous meningitis, occurs due to solid tumors and hematologic malignancies and is associated with a poor prognosis. The current management paradigm entails a multimodal approach focused on palliation with surgery, radiation, and chemotherapy, which may be administered systemically or directly into the cerebrospinal fluid (CSF). This review focuses on novel therapeutic approaches, including targeted and immunotherapeutic agents under investigation, that have shown promise in NM arising from solid tumors.
Reference90 articles.
1. Intrathecal chemotherapy for treatment of leptomeningeal dissemination of metastatic tumours;Beauchesne;Lancet Oncol.,2010
2. Leptomeningeal disease from melanoma-Poor prognosis despite new therapeutic modalities;Chorti;Eur. J. Cancer,2021
3. Current diagnosis and treatment of leptomeningeal metastasis;DeAngelis;J. Neurooncol.,1998
4. Leptomeningeal metastases in the MRI era;Clarke;Neurology,2010
5. Balestrino, R., Rudà, R., and Soffietti, R. (2020). Brain Metastasis from Unknown Primary Tumour: Moving from Old Retrospective Studies to Clinical Trials on Targeted Agents. Cancers, 12.
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献